MMEDF News and Press, Mind Medicine From 12/04/20

Are Psychedelic Stocks On Your Watch List Right Now Guess what, psychedelic stocks are a thing and penny stocks are benefiting right now. While the early rumors that magic mushroom stocks would become the next “cannabis industry”, it’s never easy believi...

MindMed is a biotech psychedelic medicine company focused on the clinical development of LSD, Ibogaine, MDMA, DMT, and psilocybin for anxiety, depression, addiction, ADHD, and more. Diverse and robust IP and drug development pipeline focusing on many underserved and large markets. ...

MindMed Upsizes Previously Announced Bought Deal Public Offering Canada NewsWire NEW YORK, Nov. 25, 2020 /THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINAT...

Oregon and DC lead the way with decriminalization. New Jersey and California may follow in Oregon's footsteps. 2021 will be a major year for Psychedelics. For further details see: Tripping Over Future Psychedelic Catalysts

MindMed to Launch Albert, A Digital Medicine Division for Psychedelic Medicines PR Newswire NEW YORK, Nov. 24, 2020 NEW YORK , Nov. 24, 2020 /PRNewswire/ -- MindMed (NEO: MMED) (OTCQB: MMEDF) (DE: MMQ), a leading psychedelic medicine biotech company, is ...

FinancialBuzz.com News Commentary New York, NY (11/17/2020) – Psychedelic medicine is emerging as a breakthrough for mental health. After decades of research, drugs like psilocybin and ketamine are finally ready to move from the lab into the pharmacy and the therapist...

MindMed Receives Approval of Protocol Design to Evaluate Microdoses of LSD For Adult ADHD In Phase 2a Clinical Trial from Swiss and Dutch Health Authorities Canada NewsWire NEW YORK and BASEL, Switzerland, Nov. 16, 2020 Project Lucy Submits Pre-IND Briefing Package...

Mind Medicine (MMEDF): Q3 Net and comprehensive loss of C$8.6MTotal assets as of Sept. 30, 2020 were C$23.7M, including C$18.2M in cash.Press Release For further details see: Mind Medicine reports Q3 results

MindMed Announces Q3 2020 Financial Results; Cash Reserves Total $37.8 million USD ($50.1 million CAD) Post October Financing PR Newswire TORONTO, Nov 13, 2020 TORONTO , Nov 13, 2020 /PRNewswire/ -- MindMed (NEO: MMED) (OTCQB: MMEDF), a leading psych...

How Biotech & Psychedelic Penny Stocks Could See New Bullish Interest in 2021 If you’ve read the title and are wondering what psychedelic stocks are, you’re not alone. This niche area of the stock market has only begun to gain traction in the past few years & ...